On August 12, 2020 Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) reported that on August 11, 2020, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting on April 24, 2015 (the "Share Option Scheme") (Press release, Hutchison China MediTech, AUG 12, 2020, https://www.chi-med.com/grant-of-share-options-under-share-option-scheme-200812/ [SID1234563472]). The scheme limit of the Share Option Scheme was refreshed on April 27, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chi-Med granted share options under its Share Option Scheme to employees to subscribe for a total of 1,155,000 Ordinary Shares represented by 231,000 American Depositary Shares ("ADSs") (each equating to five Ordinary Shares) subject to the acceptance of the grantees. Details of such share options granted prescribed are as follows:

Date of grant : August 11, 2020
Exercise price of share options granted : US$32.82 per ADS
Number of share options granted : 1,155,000 represented by 231,000 ADSs (five share options shall entitle the holder thereof to subscribe for one ADS)
Closing market price of ADSs on the date of grant : US$32.82 per ADS
Validity period of the share options : From August 11, 2020 to August 10, 2030